---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-036342"
form_type: "8-K"
ticker: "ECOR"
cik: "0001560258"
company_name: "electroCore, Inc."
filed_at: "2026-08-06T20:11:27+00:00"
generated_at: "2026-08-06T20:15:38.975126+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# electroCore Q2 2026 revenue $9.5M (+28% YoY); net loss narrows to $3.1M; raises FY 2026 guidance to >30% growth

## Summary
- Q2 net sales $9.5M, up 28% YoY from $7.4M; GAAP net loss $3.1M ($0.33/share) vs $3.7M ($0.44) prior year.
- Adjusted EBITDA net loss improved 26% to $1.8M from $2.4M.
- Quell product line sales $1.3M, up ~700% YoY; Truvaga revenue $1.3M, up 27% YoY.
- VA channel: Rx gammaCore revenue up 11% YoY; ~16,400 VA patients (2.7% penetration of addressable headache market).
- Company raises FY 2026 revenue guidance to >30% year-over-year growth; targets positive Adjusted EBITDA in Q3 2027.

## SEC filing metadata
- accession: 0001493152-26-036342
- form_type: 8-K
- ticker: ECOR
- cik: 0001560258
- company_name: electroCore, Inc.
- filed_at: 2026-08-06T20:11:27+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1560258/000149315226036342/0001493152-26-036342-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1560258/000149315226036342/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-036342
- JSON: https://secwatch.observer/filing/0001493152-26-036342.json
- Plain text: https://secwatch.observer/filing/0001493152-26-036342.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.